CSL - upcoming presentation should be well received

CSL will present numerous medical reports (ie > 20 scientific abstracts; 5 oral presentations) pertaining to its haemophilia portfolio of investigational as well as commercialised products at the annual International Society on Thrombosis and Haemostasis (ISTH) conference being held in Toronto, Canada between 20-25 June. Specifically, CSL will present pivotal clinical trial data for two of its late-stage, long-acting recombinant drugs- factor VIII SingleChain (rVIII-SingleChain) and factor IX albumin fusion protein (rIX-FP) for the treatment of haemophilia A and haemophilia B, respectively (a market opportunity worth US$7bn+ and US$1bn+, respectively). We believe CSL’s presentations at the upcoming ISTH conference will likely highlight promising data across its haemophilia programs that should be well-received by the market. (CSL, Add, price Target A$101.73)